EUVIMEDEUVIMED entdecken
EditorialOpen Access · CC BY-NC 4.0

Plain language summary: What have research studies shown about plasma-derived human factor X concentrate treatment for people living with hereditary factor X deficiency?

Miguel A Escobar, Kaan Kavakli

Therapeutic Advances in Hematology · 2026-06 · 17

DOI: 10.1177/20406207261448285 ↗

Kurz gefasst

Editorial in der Zeitschrift Therapeutic Advances in Hematology, online erschienen am 05.06.2026. Verfasst von Miguel A Escobar und 1 weiteren Autor:innen. Beteiligte Einrichtung: University of Texas Health Science Center at Houston-McGovern Medical School and the Gulf States Hemophilia and Thrombophilia Center, Houston, Texas,…. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: This summary was sponsored by Kedrion Biopharma Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

What are these studies about? Researchers looked at the latest research studies about plasma-derived human factor X concentrate (pdFX for short) for people living with hereditary factor X deficiency (HFXD for short). These people’s health and daily lives were impacted in different ways by HFXD, and their condition was classified as mild, moderate, or severe. The researchers assessed information from 5 clinical trials and 1 case series that described the bleeding symptoms and treatment that a group of people living with HFXD had. What were the results? Researchers found that pdFX has been successfully used in adults and children with HFXD to treat bleeds when they happen, to prevent bleeds, and to manage bleeding around having surgery. Researchers found that people living with HFXD had minimal side effects when they received pdFX. What do the results mean? Research studies to date have shown that pdFX is safe and effective as a treatment for people living with mild, moderate, or severe HFXD. This information will help healthcare experts to develop recommendations based on research results about pdFX treatment for people living with HFXD. What is the purpose of this plain language summary? The purpose of this plain language summary is to help you to understand the findings from recent research.

Schlagwörter

Stichwörter der Autor:innen

Plain language summaryblood clotting disorderclotting factorfactor Xhereditary factor X deficiencylay summaryplasma-derived factor Xprothrombin complex concentratesingle factor replacement therapy

Autor:innen und Institutionen

  • University of Texas Health Science Center at Houston-McGovern Medical School and the Gulf States Hemophilia and Thrombophilia Center, Houston, Texas, United States.
  • Department of Pediatrics, Division of Hemato-Oncology, Ege University Faculty of Medicine, Izmir, Turkey.

Förderung

  • This summary was sponsored by Kedrion Biopharma Inc.

Zitieren

APA

Escobar, M. A., & Kavakli, K. (2026). Plain language summary: What have research studies shown about plasma-derived human factor X concentrate treatment for people living with hereditary factor X deficiency?. Therapeutic Advances in Hematology, 17. https://doi.org/10.1177/20406207261448285

Vancouver

Escobar MA, Kavakli K. Plain language summary: What have research studies shown about plasma-derived human factor X concentrate treatment for people living with hereditary factor X deficiency?. Therapeutic Advances in Hematology. 2026;17. doi:10.1177/20406207261448285

BibTeX
@article{Escobar2026,
  author = {Escobar, Miguel A and Kavakli, Kaan},
  title = {Plain language summary: What have research studies shown about plasma-derived human factor X concentrate treatment for people living with hereditary factor X deficiency?},
  journal = {Therapeutic Advances in Hematology},
  year = {2026},
  volume = {17},
  doi = {10.1177/20406207261448285}
}
Kostenlos starten →